GlassScriptPhysician profile
Charles R Clover
NPI 1518288828
$8,989.42
in general payments reported to CMS, 2019-2025
13 companies · $1,817 in 2025
The $1,817 reported for 2025 was more than what 78% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,538 · 2020: $620 · 2021: $969 · 2022: $862 · 2023: $1,673 · 2024: $1,510 · 2025: $1,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,994 · Travel and Lodging: $5.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,993.76 |
| Travel and Lodging | $5.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,436.69 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, General - Pain Management |
| Abbott Laboratories | $1,045.71 | 2019-2025 | Proclaim, Eterna |
| Nevro Corp. | $1,031.26 | 2019-2024 | Senza |
| Nalu Medical, INC. | $363.58 | 2021-2025 | Nalu Neurostimulation System |
| Medtronic USA, INC. | $335.75 | 2019 | |
| Medtronic, INC. | $214.25 | 2022-2025 | Intellis Adaptivestim, Accurian |
| Spr Therapeutics, INC | $185.01 | 2019-2025 | Sprint Pns System |
| Avanos Medical | $127.57 | 2019 | |
| Forte Bio-Pharma LLC | $65.09 | 2025 | Prolate, Nalocet, Tanlor |
| Convatec INC. | $63.07 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $49.93 | 2025 | |
| Abbvie INC. | $46.08 | 2025 | |
| Si-Bone, INC. | $25.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Clover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.